FDA May Decide on New Use For AbbVie’s Humira

by Andrew Berens, Grace Guo, Bloomberg Industries


AbbVie’s supplemental Biologics License Application (sBLA) to expand Humira’s existing approval for ankylosing spondylitis to include the treatment of non-radiographic axial spondyloarthritis has an estimated PDUFA date of Sept. 29.



Bloomberg BRIEF Newsletters